| 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus M Aringer, K Costenbader, D Daikh, R Brinks, M Mosca, ... Arthritis & rheumatology 71 (9), 1400-1412, 2019 | 2625 | 2019 |
| Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011 H Umehara, K Okazaki, Y Masaki, M Kawano, M Yamamoto, T Saeki, ... Modern rheumatology 22 (1), 21-30, 2012 | 2288 | 2012 |
| T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-lβ Y Tanaka, DH Adams, S Hubscher, H Hirano, U Siebenlist, S Shaw Nature 361 (6407), 79-82, 1993 | 1142 | 1993 |
| A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details H Umehara, K Okazaki, Y Masaki, M Kawano, M Yamamoto, T Saeki, ... Modern rheumatology 22 (1), 1-14, 2012 | 1010 | 2012 |
| Trial of anifrolumab in active systemic lupus erythematosus EF Morand, R Furie, Y Tanaka, IN Bruce, AD Askanase, C Richez, ... New England Journal of Medicine 382 (3), 211-221, 2020 | 938 | 2020 |
| Lymphocyte interactions with endothelial cells Y Shimizu, W Newman, Y Tanaka, S Shaw Immunology today 13 (3), 106-112, 1992 | 920 | 1992 |
| Baricitinib versus placebo or adalimumab in rheumatoid arthritis PC Taylor, EC Keystone, D Van Der Heijde, ME Weinblatt, ... New England Journal of Medicine 376 (7), 652-662, 2017 | 861 | 2017 |
| The 2019 American College of Rheumatology/European league against rheumatism classification criteria for IgG4‐related disease ZS Wallace, RP Naden, S Chari, H Choi, E Della‐Torre, JF Dicaire, ... Arthritis & Rheumatology 72 (1), 7-19, 2020 | 819 | 2020 |
| Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve‐month data from a twenty‐four–month phase III randomized radiographic study D Van Der Heijde, Y Tanaka, R Fleischmann, E Keystone, J Kremer, ... Arthritis & Rheumatism 65 (3), 559-570, 2013 | 631 | 2013 |
| Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes Y Tanaka, DH Adams, S Shaw Immunology today 14 (3), 111-115, 1993 | 538 | 1993 |
| Osteoblasts and osteoclasts in bone remodeling and inflammation Y Tanaka, S Nakayamada, Y Okada Current Drug Targets-Inflammation & Allergy 4 (3), 325-328, 2005 | 485 | 2005 |
| Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial DJ Wallace, RA Furie, Y Tanaka, KC Kalunian, M Mosca, MA Petri, ... The Lancet 392 (10143), 222-231, 2018 | 480 | 2018 |
| Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis T Takeuchi, Y Tatsuki, Y Nogami, N Ishiguro, Y Tanaka, H Yamanaka, ... Annals of the rheumatic diseases 67 (2), 189-194, 2008 | 480 | 2008 |
| Janus kinase inhibitors in autoimmune diseases JJ O'Shea, A Kontzias, K Yamaoka, Y Tanaka, A Laurence Annals of the rheumatic diseases 72 (suppl 2), ii111-ii115, 2013 | 463 | 2013 |
| CD31 expressed on distinctive T cell subsets is a preferential amplifier of beta 1 integrin-mediated adhesion. Y Tanaka, SM Albelda, KJ Horgan, GA Van Seventer, Y Shimizu, ... The Journal of experimental medicine 176 (1), 245-253, 1992 | 460 | 1992 |
| Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial D Khanna, CJF Lin, DE Furst, J Goldin, G Kim, M Kuwana, Y Allanore, ... The Lancet Respiratory Medicine 8 (10), 963-974, 2020 | 428 | 2020 |
| Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system M Tokunaga, K Saito, D Kawabata, Y Imura, T Fujii, S Nakayamada, ... Annals of the rheumatic diseases 66 (4), 470-475, 2007 | 415 | 2007 |
| Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials SB Cohen, Y Tanaka, X Mariette, JR Curtis, EB Lee, P Nash, KL Winthrop, ... Annals of the rheumatic diseases 76 (7), 1253-1262, 2017 | 388 | 2017 |
| Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT … Y Nakaoka, M Isobe, S Takei, Y Tanaka, T Ishii, S Yokota, A Nomura, ... Annals of the rheumatic diseases 77 (3), 348-354, 2018 | 353 | 2018 |
| Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study Y Tanaka, T Takeuchi, T Mimori, K Saito, M Nawata, H Kameda, T Nojima, ... Annals of the rheumatic diseases 69 (7), 1286-1291, 2010 | 344 | 2010 |
